Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Approved for CLL and SLL—types of leukemia and lymphoma—Brukinsa caused fewer heart-related side effects in trials.
The Dana-Farber led ALPINE trial looked at the drug in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The newer targeted therapy zanubrutinib works better and has fewer side effects than the older ibrutinib.
Studies suggest BTK inhibitors and hormone therapy might lessen disease severity and speed recovery.
Clinical trials showed that 84% of patients saw tumor shrinkage with this therapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.